Avadel Pharmaceuticals plc has entered into an exclusive global licensing agreement with XWPharma Ltd. to develop and commercialize valiloxybate, an investigational GABAB receptor agonist and once-at-bedtime oxybate formulation for the treatment of narcolepsy and idiopathic hypersomnia. The agreement expands Avadel’s sleep medicine portfolio and reflects the company’s strategy to strengthen its position in the global … Sleep Disorder Market Heats Up with Avadel’s Global Grab for Valiloxybate Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.